Financial Performance - The Group recorded a turnover of approximately HK$230,542,000 for the year ended 31 December 2018, representing an increase of 2.4 times compared to HK$68,705,000 in 2017[20]. - Profit attributable to owners of the Company amounted to approximately HK$80,537,000, a slight increase of 0.6% from HK$80,066,000 in 2017; excluding goodwill impairment, profit increased by 22.5% to approximately HK$98,071,000[20]. - Revenue from the Healthcare Related Business was approximately HK$46,248,000, an increase of 7.5% from HK$43,036,000 in 2017, with profit from this segment rising 10.7 times to approximately HK$2,985,000[20]. - Revenue from the Trading Business was approximately HK$118,847,000, representing an increase of 107.1 times compared to HK$1,099,000 in 2017, with profit increasing 34.4 times to approximately HK$16,221,000[20]. - Revenue from the Agency Service was approximately HK$46,731,000, an increase of 2.2 times from HK$14,727,000 in 2017, with profit rising by 205.3% to approximately HK$39,991,000[25]. - Revenue from the Property Investment and Leasing Business increased by 90.1% to approximately HK$18,716,000, while profit decreased by 29.5% to approximately HK$74,943,000 due to a decrease in fair value gain on investment properties[25]. Dividends and Reserves - The Board does not recommend the payment of a final dividend for the year ended 31 December 2018[25]. - Profit attributable to shareholders before dividends was approximately HK$80,537,000 for the year ended 31 December 2018, compared to HK$80,066,000 in 2017[159]. - The aggregate amount of the Company's reserves available for distribution to its owners as of 31 December 2018 was HK$599,375,000, an increase from HK$501,050,000 in 2017[160]. - The Company did not recommend the payment of a final dividend for the year ended 31 December 2018[157]. Acquisitions and Investments - The Group acquired a 20% equity interest in Yunnan Hansu Biotechnology Co., Ltd. for RMB 60 million, completed on March 16, 2018, with a net profit of RMB 50,020,000 for the year ended December 31, 2018[26]. - Shenzhen Meilleure agreed to acquire a 45% equity interest in Shenzhen Wingor for RMB 55,278,000, enhancing its position in the health management service field[54]. - The acquisition of Shenzhen Wingor is expected to allow the Group to enter the cell and gene treatment market, solidifying its competitive position[54]. - The acquisition of Shenzhen Wingor is expected to enhance the company's competitive position in the health management sector through precision medicine and provide opportunities in the cell and gene therapy market[55]. - The acquisition was completed in February 2019, making the company the largest single shareholder of Shenzhen Wingor[55]. Financial Position - As of December 31, 2018, the group's cash and cash equivalents totaled approximately HK$161,142,000, an increase from HK$50,852,000 in 2017, primarily due to increased fundraising and bank borrowings[56]. - The group had aggregate banking facilities of HK$283,466,000 as of December 31, 2018, compared to HK$175,537,000 in 2017, with a short-term loan of HK$219,563,000 utilized[56]. - Approximately 8.43% of the group's cash and cash equivalents are denominated in Hong Kong dollars, 36.58% in RMB, and 50.61% in US dollars[56]. - The company raised HK$54,600,000 for working capital and the acquisition of the 45% equity interest in Shenzhen Wingor Biotechnology Co., Ltd.[70]. - Bank borrowings secured by the Group's assets amounted to HK$219,563,000 as of 31 December 2018, up from HK$128,287,000 in 2017[1]. - The increase in cash and cash equivalents reflects the company's successful fundraising efforts and strategic financial management[56]. - As of 31 December 2018, the gearing ratio was 23%, down from 30% in 2017, with net debt of HK$249,922,000 and equity attributable to owners of the Company amounting to HK$817,003,000[1]. Legal and Compliance - The Company is currently involved in a legal action with potential damages claimed at approximately HK$2,316,666 plus interests[146][147]. - The directors believe that there is no need to make a provision for the claim due to its preliminary stage and the nature of the acquisition of La Clinique De Paris International Limited[152]. - The Company is not aware of any tax relief or exemption available to shareholders due to their holding of the Company's securities[161]. Employment and Governance - As of December 31, 2018, the Group employed approximately 86 employees[174]. - The Directors are required to retire by rotation once every three years, with one-third of the Directors retiring at each annual general meeting[176]. - The Group's remuneration policies align with market practices and are based on individual performance and experience[174]. Research and Development - Yunnan Hansu is the first facility in China to comply with GMP standards and holds the largest extraction base for Cannabidiol (CBD) and other cannabinol substances[38]. - The cooperation with Hemp Investment Group is a strategic initiative for the Group's investment in the medical and healthcare industry[38]. - Yunnan Hansu has applied for 17 patents and is recognized as a leading benchmark in the hemp industry globally[39].
美瑞健康国际(02327) - 2018 - 年度财报